Who Owns Insulet Company?

Who Owns Insulet Corporation?

Understanding Insulet Corporation's ownership is key to grasping its strategic path and accountability. Since its 2007 IPO, the company has evolved from private to public ownership, broadening its investor base significantly.

Insulet, a medical technology firm founded in 2000, is dedicated to simplifying diabetes management with its innovative insulin delivery systems, notably the Omnipod Insulin Management System. This tubeless, wearable pump offers a discreet and convenient solution for those managing insulin-dependent diabetes, integrating digital health for comprehensive care.

Who owns Insulet Company?

As of July 2025, Insulet holds a market capitalization of approximately $20.42 billion, ranking it as the 1046th most valuable company globally. The company achieved a significant milestone in 2024, surpassing $2 billion in revenue for the first time. This growth reflects its strong market presence and strategic advancements, including its Insulet BCG Matrix analysis.

Insulet Corporation was established in the year 2000 by its founders John Brooks, Amparo Diaz, and Duane DeSisto. The company's initial vision centered on pioneering advanced drug delivery systems, spurred by a personal drive to improve insulin delivery for a family member. This foundational goal guided its early development and subsequent funding efforts.

Founding Vision

Insulet was founded in 2000 with a mission to revolutionize drug delivery. The impetus came from a founder's desire to create a superior insulin delivery method.

Initial Funding

The company secured its first external capital in 2001, a venture capital round totaling $5 million. This funding was critical for early-stage development and operations.

Venture Capital Support

Early institutional investors were instrumental in Insulet's growth. These partnerships provided essential resources for product innovation and market expansion.

Series E Financing

In February 2006, Insulet successfully raised $50 million in a Series E funding round. OrbiMed Advisors LLC led this significant investment, joined by other key venture capital firms.

Product Development

The capital raised fueled the development of the Omnipod system, which commenced in 2003. This innovation marked a significant step in the company's product pipeline.

Growth and Expansion

Funds were allocated to expand manufacturing capacity and support further product development and clinical trials. This strategy aimed to meet increasing market demand.

While precise initial equity distributions among the founders are not publicly disclosed, the early investment rounds were vital for Insulet's progression. The company's strategic use of capital, as highlighted by then-President and CEO Duane DeSisto, focused on scaling operations and advancing its innovative product portfolio. Understanding the Marketing Strategy of Insulet provides further context on how these early investments translated into market presence.

Insulet Corporation's journey from a private entity to a publicly traded company began with its Initial Public Offering (IPO) on May 15, 2007. This significant event marked a new era for Insulet ownership, allowing broader participation in its growth and development.

As of March 31, 2025, the Insulet Corporation ownership structure is predominantly held by institutional investors. These large entities play a crucial role in shaping the company's strategic direction and governance through their substantial shareholdings and active engagement.

Insulet's Major Shareholders

Institutional investors are the primary Insulet shareholders, collectively owning a significant portion of the company. This concentration of ownership by financial institutions highlights their confidence in Insulet's market position and future prospects.

• The Vanguard Group, Inc.: 12.3% (valued at approx. $2.5 billion)
• FMR LLC (Fidelity Management & Research Co. LLC): 11.07% (valued at approx. $2.117 billion)
• BlackRock, Inc.: 9.11%
• Capital Research Global Investors: 8.63%
• Clearbridge Investments, Llc.: 5.239%
• Invesco Ltd.: 13.239%
• State Street Corp.: 4.30%
• Baillie Gifford & Co.: 3.20%
• Geode Capital Management LLC: 2.66%
• Fil Ltd.: -10.196%

Insulet insiders hold approximately 24.96% of the company's stock, indicating a strong alignment between management and ownership. Understanding the Target Market of Insulet can provide further context to these ownership dynamics.

The governance of Insulet Corporation is overseen by its Board of Directors, a group responsible for strategic direction and fiduciary duties. As of April 2025, Ashley McEvoy holds the positions of President and Chief Executive Officer, also serving as a board member. Timothy Scannell chairs Insulet's Board of Directors.

Insulet operates under a standard one-share-one-vote structure, meaning voting power is directly tied to the number of shares held. Major institutional shareholders, whose influence is detailed in discussions about Brief History of Insulet, exert their voting power through their substantial equity stakes. This was evident at the May 22, 2025, Annual Meeting of Stockholders, where shareholders elected Class III directors and approved executive compensation. The company's 2025 Stock Option and Incentive Plan also received shareholder approval, signaling confidence in the company's strategic direction and governance.

Shareholder Influence and Voting

Shareholder influence at Insulet is primarily driven by the number of shares owned. The company utilizes a traditional voting structure.

• Voting power is proportional to share ownership.
• Institutional investors hold significant voting influence.
• Shareholder approval is required for key corporate actions.
• No major proxy battles have been reported recently.

Insulet Corporation has seen significant shifts in its leadership and ownership trends over the past few years. A key development was the appointment of Ashley McEvoy as President and CEO on April 28, 2025, succeeding Jim Hollingshead, under whom the company achieved a 26% revenue growth CAGR from 2022 to 2024.

Insulet's financial performance demonstrates robust growth, with revenues exceeding $2 billion in 2024 and a significant year-over-year increase in the first quarter of 2025. The company’s market capitalization has also seen substantial appreciation, reflecting strong investor confidence. Institutional investors continue to be the primary holders of Insulet stock, with recent data showing over 101% ownership as of March 2025, indicating a high level of institutional commitment and belief in the company's future, particularly as it expands its global reach. Understanding the Competitors Landscape of Insulet provides further context to these ownership trends.

Leadership Evolution

Ashley McEvoy took over as CEO in April 2025. This leadership change aligns with the company's aggressive international expansion plans for 2025.

Financial Momentum

The company reported over $2 billion in revenue for 2024, a 22.1% increase. First quarter 2025 revenue reached $569 million, up 28.82% year-over-year.

Market Valuation Growth

Insulet's market capitalization surged by 47.52% in one year, reaching $20.42 billion by July 2025. This growth underscores increasing investor interest.

Institutional Investor Activity

Institutional investors held approximately 101.16% of shares as of March 2025. Significant stake increases were noted from firms like Federated Hermes and GAMMA Investing.